Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emlenoflast - Roche

Next Previous
Search
Drug Profile

Emlenoflast - Roche

Alternative Names: Inzomelid; IZD-174; MCC-7840

Latest Information Update: 16 Dec 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inflazome
  • Developer Roche
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cryopyrin-associated periodic syndromes

Most Recent Events

  • 12 Dec 2022 No development reported - Phase-II for Cryopyrin-associated periodic syndromes in United Kingdom (PO)
  • 02 Dec 2020 Inflazome withdraws a pharmacokinetic phase I trial in Parkinson's disease due to strategic decision (PO) (NCT04338997)
  • 22 Sep 2020 Phase-II clinical trials in Cryopyrin-associated periodic syndromes in United Kingdom (PO) (EudraCT2020-000489-40)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top